Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus - 08/08/11
, Peter C.M. van de Kerkhof, MD, PhD, Elke M.J.G. de Jong, MD, PhD, Marieke M.B. Seyger, MD, PhD
Reprint requests: H. Jorn Bovenschen, MD, PhD, Department of Dermatology, University Medical Center St Radboud, PO Box 9101, NL-6500 HB Nijmegen, The Netherlands.Abstract |
Background |
Treatment of chronic discoid lupus erythematosus (CDLE) with a pulsed dye laser (PDL) has shown promising results, although outcomes in previous studies were not validated and laser parameters were inconsistent.
Objective |
We conducted an open prospective study to assess the efficacy and safety of PDL for the treatment of recalcitrant CDLE, using a validated scoring method and a fixed treatment schedule.
Methods |
Twelve patients with active CDLE lesions were treated with PDL (585 nm, fluence 5.5 J/cm2, spot size 7 mm) 3 times with an interval of 6 weeks followed by a 6-week follow-up period. Treatment outcomes were evaluated by 3 observers using the validated Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). Cosmetic results and adverse events were recorded.
Results |
A significant decline in “active” CLASI was observed after 6 weeks, after 12 weeks, and at follow-up. Baseline active CLASI was 4.4 ± 0.2 (mean ± SEM), reaching 1.3 ± 0.3 after follow-up (P < .0001). Individual scores for erythema and scaling/hypertrophy significantly declined 6 weeks after treatment. The “damage” CLASI (dyspigmentation, scarring, and atrophy) did not show any significant change during or after therapy. The observed clinical improvement was confirmed by two independent observers by clinical assessment of photographs (r = 0.87 and r = 0.89; both P < .05). The treatment was well tolerated, only minimal pain was reported, and the cosmetic result was fair.
Limitations |
Small sample size and short follow-up duration were limitations.
Conclusion |
PDL treatment is an effective and safe therapy for patients with refractory CDLE.
Le texte complet de cet article est disponible en PDF.Abbreviations used : CDLE, CLASI, PDL, VAS
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 60 - N° 4
P. 626-632 - avril 2009 Retour au numéro
Article précédent
- A randomized double-blind trial of intravenous immunoglobulin for pemphigus
- Masayuki Amagai, Shigaku Ikeda, Hiroshi Shimizu, Hajime Iizuka, Katsumi Hanada, Setsuya Aiba, Fumio Kaneko, Seiichi Izaki, Kunihiko Tamaki, Zenro Ikezawa, Masahiro Takigawa, Mariko Seishima, Toshihiro Tanaka, Yoshiki Miyachi, Ichiro Katayama, Yuji Horiguchi, Sachiko Miyagawa, Fukumi Furukawa, Keiji Iwatsuki, Michihiro Hide, Yoshiki Tokura, Masutaka Furue, Takashi Hashimoto, Hironobu Ihn, Sakuhei Fujiwara, Takeji Nishikawa, Hideoki Ogawa, Yasuo Kitajima, Koji Hashimoto, Pemphigus Study Group
- Classification of cutaneous intravascular breast cancer metastases based on immunolabeling for blood and lymph vessels
- Alexander G. Marneros, Fiona Blanco, Sameera Husain, David N. Silvers, Marc E. Grossman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?